Anthranilamide inhibitors of factor Xa

被引：18

作者：

Mendel, David ^{[1
]}

Marquart, Angela L. ^{[1
]}

Joseph, Sajan ^{[1
]}

Waid, Philip ^{[1
]}

Yee, Ying K. ^{[1
]}

Tebbe, Anne Louise ^{[1
]}

Ratz, Andrew M. ^{[1
]}

Herron, David K. ^{[1
]}

Goodson, Theodore ^{[1
]}

Masters, John J. ^{[1
]}

Franciskovich, Jeffry B. ^{[1
]}

Tinsley, Jennifer M. ^{[1
]}

Wiley, Michael R. ^{[1
]}

Weir, Leonard C. ^{[1
]}

Kyle, Jeffrey A. ^{[1
]}

Klimkowski, Valentine J. ^{[1
]}

Smith, Gerald F. ^{[1
]}

Towner, Richard D. ^{[1
]}

Froelich, Larry L. ^{[1
]}

Buben, John ^{[1
]}

Craft, Trelia J. ^{[1
]}

机构：

[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 17期

关键词：

protease inhibitor; factor Xa; anticoagulant;

D O I：

10.1016/j.bmcl.2007.06.051

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

SAR about the B-ring of a series of N-2-aroyl anthranilamide factor Xa (tXa) inhibitors is described. B-ring o-aminoalkylether and B-ring p-amine probes of the S1' and S4 sites, respectively, afforded picomolar fXa inhibitors that performed well in in vitro anticoagulation assays. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：4832 / 4836

页数：5

共 50 条

[31] Recent advances in Factor Xa inhibitors
Betz, A
EXPERT OPINION ON THERAPEUTIC PATENTS, 2001, 11 (06) : 1007 - 1017
[32] Oral Direct Factor Xa Inhibitors
Yeh, Calvin H.
Fredenburgh, James C.
Weitz, Jeffrey I.
CIRCULATION RESEARCH, 2012, 111 (08) : 1069 - 1078
[33] Anticoagulants: Thrombin and factor Xa inhibitors
Fevig, JM
Wexler, RR
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 34, 1999, 34 : 81 - 100
[34] Efficacy and Toxicity of Factor Xa Inhibitors
Bondarenko, Maryna
Curti, Christophe
Montana, Marc
Rathelot, Pascal
Vanelle, Patrice
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2013, 16 (01): : 74 - 88
[35] Cardiovascular agents: Renin inhibitors and factor Xa inhibitors
Kasani, Aparna
Subedi, Rajendra
Stier, Michael
Holsworth, Daniel D.
Maiti, Sarnarendra N.
HETEROCYCLES, 2007, 73 (01) : 47 - +
[36] Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors
Remko, Milan
Remkova, Anna
Broer, Ria
MOLECULES, 2016, 21 (02)
[37] From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa.: Part 3
Doennecke, Daniel
Schweinitz, Andrea
Stuerzebecher, Anne
Steinmetzer, Peter
Schuster, Maj
Stuerzebecher, Uta
Nicklisch, Silke
Stuerzebecher, Joerg
Steinmetzer, Torsten
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (12) : 3322 - 3329
[38] MEDI 394-Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties
Corte, James R.
Fang, Tianan
Pinto, Donald J. P.
Han, Wei
Hu, Zilun
Jiang, Xiang-Jun
Li, Yun-Long
Rendina, Alan R.
Luettgen, Joseph M.
Wong, Pancras C.
He, Kan
Chang, Chong-Hwan
Cheney, Daniel L.
Knabb, Robert M.
Wexler, Ruth R.
Lam, Patrick Y. S.
Gauuan, Jolicia F.
Hadden, Mark
Orton, Darren
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
[39] Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
Verhoef, Daniel
Visscher, Koen M.
Vosmeer, C. Ruben
Cheung, Ka Lei
Reitsma, Pieter H.
Geerke, Daan P.
Bos, Mettine H. A.
NATURE COMMUNICATIONS, 2017, 8
[40] Bleeding under the Medication of Factor Xa Inhibitors
Dovjak, Peter
ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2019, 52 (04): : 392 - 392

← 1 2 3 4 5 →